A successfully cured case of cytomegalovirus multiple organ infection after hematopoietic stem cell transplantation: A case report

Li,Qiqi; Liang,Quan; Meng,Rongmei; Xie,Qingqiao; Zhang,Yingzhen; Wei,Changjin; Wei,Yunjie; He,Kaiye; Li,Meihua

doi:10.3892/etm.2023.12153

A successfully cured case of cytomegalovirus multiple organ infection after hematopoietic stem cell transplantation: A case report

Authors:
- Qiqi Li
- Quan Liang
- Rongmei Meng
- Qingqiao Xie
- Yingzhen Zhang
- Changjin Wei
- Yunjie Wei
- Kaiye He
- Meihua Li
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Autonomous Region 530021, P.R. China
Published online on: August 4, 2023 https://doi.org/10.3892/etm.2023.12153
Article Number: 454
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytomegalovirus (CMV) infection is one of the most common infectious complications following hematopoietic stem cell transplantation (HSCT); however, cases involving multiple organs at the same time are rare. The present study describes a case of CMV pneumonia combined with CMV DNAemia and CMV cystitis after HSCT. A 33‑year‑old male patient with acute myeloid leukemia was treated with HSCT. The first month after HSCT, the patient developed a cough and shortness of breath. At 2 months post‑HSCT, the patient developed hematuria. The CMV DNA levels in the blood and urine were elevated; bronchoalveolar lavage fluid (BALF) was also positive for CMV DNA. Heterotypic cells exhibiting a large nuclear morphology were observed in the BALF and bronchial brushes. Recurrent and progressive ground‑glass opacities were evident on chest computed tomography. The patient was diagnosed with CMV pneumonia complicated by CMV DNAemia and CMV cystitis, and was treated with a combination of ganciclovir and foscarnet, along with immunoglobulin therapy. The patient was cured and discharged. It was determined that the CMV DNA in the blood was inconsistent with that in the BALF, which delayed the early diagnosis of CMV pneumonia. The association between T‑cell immune function and the therapeutic efficacy for CMV multi‑organ infection following HSCT is known to be significant. Moreover, the timely administration of ganciclovir and foscarnet in combination with immunoglobulin therapy demonstrated favorable clinical outcomes.

View Figures

View References

1	Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, et al: Worldwide network of blood and marrow transplantation. Hematopoietic stem cell transplantation: A global perspective. JAMA. 303:1617–1624. 2010.PubMed/NCBI View Article : Google Scholar
2	Moss P and Rickinson A: Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol. 5:9–20. 2005.PubMed/NCBI View Article : Google Scholar
3	Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C and Ward KN: 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 19:e260–e272. 2019.PubMed/NCBI View Article : Google Scholar
4	Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, et al: Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis. Blood. 127:2427–2438. 2016.PubMed/NCBI View Article : Google Scholar
5	Zhou X, Jin N and Chen B: Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation. Oncol Lett. 21(318)2021.PubMed/NCBI View Article : Google Scholar
6	Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, Flowers ME, Corey L and Boeckh M: Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 61:31–39. 2015.PubMed/NCBI View Article : Google Scholar
7	Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V and Griffiths PD: Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 64:87–91. 2017.PubMed/NCBI View Article : Google Scholar
8	Rozy A, Duk K, Szumna B, Skronska P, Gawryluk D and Chorostowska-Wynimko J: Effectiveness of PCR and immunofluorescence techniques for detecting human cytomegalovirus in blood and bronchoalveolar lavage fluid. Adv Exp Med Biol. 921:21–26. 2016.PubMed/NCBI View Article : Google Scholar
9	Seok JY, An J, Ha SY, Chung DH, Lee S and Kim H: Morphologic analysis of cytomegalovirus infected cells in bronchial washing cytology: Comparison of liquid-based preparation and conventional smear. J Pathol Transl Med. 50:147–154. 2016.PubMed/NCBI View Article : Google Scholar
10	Elfeky R, Lazareva A, Qasim W and Veys P: Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Rev Clin Immunol. 15:735–751. 2019.PubMed/NCBI View Article : Google Scholar
11	Alexandersson A, Koskenvuo M, Tiderman A, Lääperi M, Huttunen P, Saarinen-Pihkala U, Anttila VJ, Lautenschlager I and Taskinen M: Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation. Infect Dis (Lond). 51:772–778. 2019.PubMed/NCBI View Article : Google Scholar
12	Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, Howard JF, Chopra M, Liu W and Yi JS: Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Exp Neurol. 312:43–50. 2019.PubMed/NCBI View Article : Google Scholar
13	Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, Gupta S, Smits W, Pituch-Noworolska A and Strach M: Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. Eur J Pharm Sci. 118:80–86. 2018.PubMed/NCBI View Article : Google Scholar
14	Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, Ritchie DJ, Westervelt P and Dubberke ER: Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 30:554–561. 2010.PubMed/NCBI View Article : Google Scholar
15	Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, et al: CMV management with specific immunoglobulins: A multicentric retrospective analysis on 92 allotransplanted patients. Mediterr J Hematol Infect Dis. 11(e2019048)2019.PubMed/NCBI View Article : Google Scholar
16	Törlén J, Gaballa A, Remberger M, Mörk LM, Sundberg B, Mattsson J and Uhlin M: Effect of graft-versus-host disease prophylaxis regimens on T and B cell reconstitution after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 25:1260–1268. 2019.PubMed/NCBI View Article : Google Scholar